Skip to main content

Stimulation of respiratory immunity by oral administration of Lactococcus lactis

Buy Article:

$50.00 plus tax (Refund Policy)

Abstract:

This work demostrates that nonrecombinant Lactococcus lactis NZ, administered by the oral route at the proper dose, is able to improve resistance against pneumococcal infection. Lactococcus lactis NZ oral administration was able to improve pathogen lung clearance, increased survival of infected mice, and reduced lung injuries. This effect was related to an upregulation of the respiratory innate and specific immune responses. Administration of L. lactis NZ improved production of bronchoalveolar lavage (BAL) fluid TNF-α, enhanced recruitment of neutrophils into the alveolar spaces, and induced a higher activation of BAL phagocytes compared with the control group. Lactococcus lactis NZ administered orally stimulated the IgA cycle, increased IgA+ cells in intestine and bronchus, and improved production of BAL IL-4 and IL-10 during infection. Moreover, mice treated with L. lactis NZ showed higher levels of BAL anti-pneumococcal IgA and IgG. Taking into consideration that orally administered L. lactis NZ stimulates both the innate and the specific immune responses in the respiratory tract and that bacterial and viral antigens have been efficiently produced in this strain, L. lactis NZ is an excellent candidate for the development of an effective pneumococcal oral vaccine.

Ce travail démontre que Lactococcus lactis NZ non recombinante, administrée par voie orale à une dose appropriée, peut améliorer la résistance aux infections à pneumocoques. L’administration par voie orale de L. lactis NZ peut améliorer l’élimination du pathogène des poumons, augmenter la survie des souris infectées et réduire les dommages pulmonaires. Cet effet est relié à l’augmentation des réponses immunes respiratoires innées et spécifiques. L’administration de L. lactis NZ a amélioré la production de TNF-α recueilli du liquide de lavage broncho-alvéolaire (LBA), a augmenté le recrutement des neutrophiles dans les espaces alvéolaires, et a induit une plus forte activation des phagocytes du LBA comparativement au groupe contrôle. Lactococcus lactis NZ administrée oralement a stimulé la production d’IgA, a augmenté le nombre de cellules IgA+ dans l’intestin et les bronches et a amélioré la production d’IL-4 et d’IL-10 du LBA lors de l’infection. De plus, les souris traitées avec L. lactis NZ ont présenté de plus hauts niveaux d’IgA et d’IgG anti-pneumocoque dans le LBA. Considérant que L. lactis NZ administrée par voie orale stimule aussi bien la réponse immune innée que spécifique des voies respiratoires et que des antigènes bactériens et viraux ont été produits efficacement chez cette souche, L. lactis NZ est une excellente candidate pour développer un vaccin anti-pneumocoque oral efficace.

Document Type: Research Article

Publication date: August 1, 2008

More about this publication?
  • Published since 1954, this monthly journal contains new research in the field of microbiology including applied microbiology and biotechnology; microbial structure and function; fungi and other eucaryotic protists; infection and immunity; microbial ecology; physiology, metabolism and enzymology; and virology, genetics, and molecular biology. It also publishes review articles and notes on an occasional basis, contributed by recognized scientists worldwide.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Terms & Conditions
  • Sample Issue
  • Reprints & Permissions
  • Ingenta Connect is not responsible for the content or availability of external websites

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more